Current issue
Archive
Manuscripts accepted
About the journal
Editorial board
Abstracting and indexing
Contact
Instructions for authors
Ethical standards and procedures
Editorial System
Submit your Manuscript
|
1/2018
vol. 93 abstract:
Original paper
Treatment-related gonadotoxicity in young male cancer survivors: a comparative cross-sectional study
Maryna Krawczuk-Rybak
,
Marcin Plonowski
,
Beata Zelazowska-Rutkowska
,
Malgorzata Wojtkowska
,
Bogdan Cylwik
,
Jolanta Skalska-Sadowska
,
Jacek Wachowiak
,
Dorota Sega-Pondel
,
Bernadeta Kazanowska
,
Teresa Stachowicz-Stencel
,
Joanna Stefanowicz
,
Iwona Malinowska
,
Michal Matysiak
,
Andrzej Koltan
,
Mariusz Wysocki
,
Aneta Pobudejska-Pieniazek
,
Tomasz Szczepanski
,
Borys PrzybyszewskI
,
Wanda Badowska
,
Aneta Czajnska-Deptula
,
Bozenna Dembowska-Baginska
,
Dorota Slawinska
,
Jerzy Kowalczyk
,
Elzbieta Kamienska
,
Tomasz Urasinski
,
Anna Wawrzenczyk
Pediatr Pol 2018; 93 (1): 23–29
Online publish date: 2018/03/19
View
full text
Get citation
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
Introduction
Male gonads are susceptible to the deleterious effect of anticancer therapy (chemotherapy, radiation to the pelvis, central nervous system, or total body irradiation). Hormonal dysfunction after anticancer treatment was evaluated in young male cancer survivors. Material and methods In 153 male adolescent cancer survivors divided into three risk groups (low-LR, moderate-MR, and high-HR) and 24 controls, gonadal and pituitary hormones were analysed. FSH, LH, and testosterone levels were assessed in all the studied patients using immunoenzymatic techniques, dimeric inhibin B – by ELISA method. Results All cancer survivor groups had lower mean values of inhibin B (86.87 ±69.07 ng/l vs. 161.07 ±60.64 ng/l; p < 0.001), and higher FSH (10.23 ±13.35 mIU/l vs. 4.38 ±2.39 mIU/l; p < 0.001) and LH (5.0 ±3.43 IU/l vs. 3.58 ±2.17 IU/l; p = 0.016); testosterone levels were comparable to the controls. Abnormal values of inhibin B were found: in 15.2% of survivors in LR, 47.6% in MR, and 94.1% – in the HR group. Elevated FSH levels were seen in 20.4% of survivors in LR, 47.4% in MR, and 92.2% in the HR group. The inhibin B: FSH ratio was lowered in MR and HR risk groups. We did not observe any influence of the age at treatment and the time since treatment termination on the analysed hormonal values. Conclusions Anticancer treatment increases the risk of gonadal damage, particularly in the HR group. Patients and parents ought to be informed about the risk of lowered reproductive function, and pretreatment semen cryopreservation should be recommended. keywords:
childhood cancer survivors, late effect, fertility, gonadal function, inhibin B |